Morningstar Fund Report  | 02/04/2025Print

Pictet-Biotech I dy GBP

Performance History31/03/2025
Growth of 1,000 (GBP) Advanced Graph
Pictet-Biotech I dy GBP
Fund-6.7-4.58.91.2-10.9
+/-Cat2.33.410.24.2-5.1
+/-B’mrk-7.0-6.91.67.8-7.4
 
Category: Sector Equity Biotechnology
Category Benchmark: Morningstar Gbl Biotechnolo...
Key Stats
NAV
01/04/2025		 GBP 759.52
Day Change -0.25%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector Specialist
ISIN LU0448836352
Fund Size (Mil)
01/04/2025		 USD 1194.89
Share Class Size (Mil)
01/04/2025		 GBP 9.19
Max Initial Charge 5.00%
Ongoing Charge
07/02/2025		  1.10%
Investment Objective: Pictet-Biotech I dy GBP
To increase the value of your investment while seeking to achieve a positive social impact. The Fund applies a sustainable strategy and invests at least two-thirds of its net assets in equities or similar securities issued by biopharmaceutical companies throughout the world. Companies supporting the health of people with high innovation capacity. Better therapies can deliver true value to patients and healthcare systems alike. These companies are tackling high unmet medical needs and reduce the pressures on healthcare budgets through the reduction of hospital admissions or symptom management. The Fund invests mainly in companies whose significant proportion of their activities are related to, but not limited to, new mechanisms of actions offering potential cures or management of diseases that were hard to treat before, technology platforms, research tools and services in the biotechnology value chain as well as the improvement of therapies or drugs.
Returns
Trailing Returns (GBP)01/04/2025
YTD-11.14
3 Years Annualised2.77
5 Years Annualised2.93
10 Years Annualised2.75
12 Month Yield 0.00
Dividend Paying Frequency Annually
Management
Manager Name
Start Date
Tazio Storni
26/05/2016
Marco Minonne
01/06/2020
Click here to see others
Inception Date
10/09/2009

Category Benchmark
Fund BenchmarkMorningstar Benchmark
MSCI ACWI NR EURMorningstar Gbl Biotechnology NR USD
Portfolio Profile for  Pictet-Biotech I dy GBP28/02/2025
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock99.010.0099.01
Bond0.110.000.11
Property0.000.000.00
Cash1.650.770.88
Other0.000.000.00
Top 5 Regions%
United States90.03
Eurozone3.80
Europe - ex Euro2.41
United Kingdom1.98
Canada1.79
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Gilead Sciences IncHealthcareHealthcare6.57
Insmed IncHealthcareHealthcare5.17
argenx SE ADRHealthcareHealthcare4.87
Regeneron Pharmaceuticals IncHealthcareHealthcare3.55
SpringWorks Therapeutics Inc Ord... HealthcareHealthcare3.08
Increase Decrease New since last portfolio
Pictet-Biotech I dy GBP
Growth Of 1000 (GBP) 31/03/2025
Fund:  Pictet-Biotech I dy GBP
Category:  Sector Equity Biotechnology
Category Index:  Morningstar Gbl Biotechnology NR USD
Growth of 1,000 GBP
Annual Returns (GBP)31/03/2025
 201820192020202120222023202431/03
Price Return-9.3027.8524.89-6.72-4.478.891.25-10.93
+/- Category-1.337.65-1.082.313.3710.174.17-5.05
+/- Category Index-7.4511.14-8.05-7.02-6.931.567.82-7.44
% Rank in Category69162560611736-
Trailing Returns (GBP)01/04/2025
   Total Returns   +/- Category   +/- Category Index
1 Day-0.25   1.150.53
1 Week-7.50   -4.17-2.98
1 Month-9.61   -3.52-1.69
3 Months-11.14   -6.17-6.92
6 Months-12.43   -6.014.63
YTD-11.14   -6.17-6.92
1 Year-14.15   -6.003.60
3 Years Annualised2.77   2.870.91
5 Years Annualised2.93   -0.59-2.89
10 Years Annualised2.75   -1.32-2.96
 
Category: Sector Equity Biotechnology
Category Index: Morningstar Gbl Biotechnology NR USD
Quarterly Returns (GBP)31/03/2025
 Quarter 1Quarter 2Quarter 3Quarter 4
2025-10.93---
20244.790.88-2.78-1.49
2023-6.513.74-1.1313.55
2022-14.95-1.8019.29-4.11
2021-4.001.022.30-5.97
2020-4.3127.560.741.56
 
 
 
Morningstar Rating™(Relative to Category)28/02/2025
 Morningstar ReturnMorningstar RiskMorningstar Rating™
3-YearAbove AverageAbove Average4 star
5-YearAverageAbove Average3 star
10-YearAverageAbove Average3 star
Overall*AverageAbove Average3 star
 
Category :  Sector Equity BiotechnologyClick here to see our Methodology
Volatility Measurements31/03/2025
 
3-Yr Std Dev21.46 %
3-Yr Mean Return5.61 %
 
3-Yr Sharpe Ratio0.07
 
Modern Portfolio Statistics31/03/202531/03/2025
 Standard IndexBest Fit Index
 Morningstar Gbl Biotechnology NR USD  Morningstar Gbl Biotechnology NR USD
3-Yr Beta0.920.89
3-Yr Alpha1.552.02
 
Investment Style Details28/02/2025
Morningstar Style Box®
Equity Style
SizeRel to Cat
Average Mkt Cap (Mil)USD 8165-
Market Capitalisation% of Equity
Giant0.00
Large14.25
Medium26.12
Small39.82
Micro19.82
Valuations and Growth RatesEquity PortfolioRelative to Category
Price/Prospective Earnings17.360.96
Price/Book3.751.07
Price/Sales6.131.17
Price/Cash Flow18.891.10
Dividend-Yield Factor0.290.80
 
Long-Term Projected Earnings Growth3.000.20
Historical Earnings Growth-16.011.33
Sales Growth14.432.23
Cash-Flow Growth-4.510.42
Book-Value Growth7.961.07
 
Category: Sector Equity Biotechnology
Asset Allocation28/02/2025
Asset Allocation
 % Long% Short% Net Assets
Stock99.010.0099.01
Bond0.110.000.11
Property0.000.000.00
Cash1.650.770.88
Other0.000.000.00
World Regions28/02/2025
 % of EquityRelative to Category
United States90.031.09
Canada1.791.43
Latin America0.000.00
United Kingdom1.980.54
Eurozone3.800.87
Europe - ex Euro2.410.41
Europe - Emerging0.00-
Africa0.00-
Middle East0.000.00
Japan0.000.00
Australasia0.000.00
Asia - Developed0.000.00
Asia - Emerging0.000.00
 
Category: Sector Equity Biotechnology
Sector Weightings28/02/2025
 % of EquityRelative to Category
HealthcareHealthcare100.001.00
 
Category: Sector Equity Biotechnology
Top 10 Holdings28/02/2025
 Portfolio NEW
Total Number of Equity Holdings64
Total Number of Bond Holdings0
Assets in Top 10 Holdings37.96
NameSectorCountry% of Assets
Gilead Sciences Inc206United States6.57
Insmed Inc206United States5.17
argenx SE ADR206United States4.87
Regeneron Pharmaceuticals Inc206United States3.55
SpringWorks Therapeutics Inc Ordinary... 206United States3.08
Sarepta Therapeutics Inc206United States3.07
Alnylam Pharmaceuticals Inc206United States3.03
Amgen Inc206United States2.94
TG Therapeutics Inc206United States2.86
Vaxcyte Inc Ordinary Shares206United States2.83
 
Increase Decrease New since last portfolio
Category: Sector Equity Biotechnology
 
Management
Name of CompanyPictet Asset Management (Europe) SA
Phone+352 467 171-1
Websitewww.am.pictet
Address15, avenue J.F. Kennedy
 Luxembourg   L-1855
 Luxembourg
DomicileLuxembourg
Legal StructureSICAV
UCITSYes
Inception Date10/09/2009
Fund Advisor(s)
Pictet Asset Management SA
Fund ManagerTazio Storni
Manager Start Date26/05/2016
Fund ManagerMarco Minonne
Manager Start Date01/06/2020
Career Start Year2000
 
Biography
Marco Minonne, CFA, Senior Vice President, rejoined the firm in 2013. Marco is part of the Growth Equity Group which is responsible for Neuberger Berman’s Mid Cap Growth and Small Cap Growth strategies. He is an Associate Portfolio Manager on Small Cap Growth and a Research Analyst covering the health care sector on Mid Cap Growth. Prior to rejoining Neuberger Berman, Marco was a senior therapeutic analyst with Columbia Management. He has previously held research analyst positions at Citadel Investment Group, Neuberger Berman and Northern Trust Bank. Marco has extensive buy-side experience in health care and has been involved in both long-only and long-short strategies. Marco earned a Bachelor of Arts in Finance and Economics from the University of Iowa and has been awarded the Chartered Financial Analyst designation.
Fund ManagerLydia Haueter
Manager Start Date26/05/2016
Fund ManagerEugénio Martin-Fougeroux
Manager Start Date01/01/2023
Fees and Expenses
Sales Charges (Maximum) 
Max Initial Charge5.00%
Max Exit Charge*1.00%
Annual Charges
Max Annual Management Charge1.20%
Ongoing Charge1.10%
Purchase Details
Minimum Investments
Initial1000000  GBP
Additional-
Savings-
Tax Free Savings Schemes
ISAsYes